Reactivation of dormant cutaneous <i>Leishmania</i> infection in a kidney transplant patient

Mirzabeigi, Marjan; Farooq, Uzma; Baraniak, Sean; Dowdy, Lorraine A.; Ciancio, Gaetano; Vincek, Vladimir

doi:10.1111/j.1600-0560.2006.00532.x

Cited by 35 publications

(37 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2006, Mirzabeigi et al reported reactivation of cutaneous leishmaniasis in a female patient after kidney transplantation [8]. The patient had a dormant Leishmania infection prior to renal transplantation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Reactivation of Cutaneous Leishmaniasis after Renal Transplantation: A Case Report

Mortazavi

Salehi

Kamyab

2014

Case Reports in Dermatological Medicine

View full text Add to dashboard Cite

A 45-year-old man with reactivation of previously existing and subsiding cutaneous leishmaniasis on his wrist and lower leg (shin) after renal transplantation was admitted to our dermatology service on March 2008. He presented to us with two huge tumoral and cauliflower-like lesions. Skin smear and histopathology of skin showed leishman bodies and confirmed the diagnosis. After renal transplantation, he received cyclosporine plus prednisolone to induce immunosuppression and reduce the probability of transplant rejection. After immunosuppressive therapy, reactivation of cutaneous leishmaniasis with the above presentation took place. The patient responded to 800 mg/day intravenous sodium stibogluconate for 3 weeks plus local cryotherapy. Systemic plus local therapy along with reducing the doses of immunosuppressive drugs led to improvement of lesions. Reactivation of leishmaniasis after immunosuppression has been rarely reported.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In the Giemsa stained slide, amastigotes were shown in histiocytes. In this patient, reactivation of cutaneous leishmaniasis was due to high doses of immunosuppressive drugs after transplantation [8]. …”

Section: Discussionmentioning

confidence: 99%

Reactivation of Cutaneous Leishmaniasis after Renal Transplantation: A Case Report

Mortazavi

Salehi

Kamyab

2014

Case Reports in Dermatological Medicine

View full text Add to dashboard Cite

show abstract

“…Bone marrow or solid organ transplantation [89][90][91][92][93][94][95] and therapy with immunosuppressive or biologic drugs [96][97][98] also have been associated with the appearance of ATL. In immunosuppressed patients, CL is characterized by atypical cutaneous lesions and persistent negativity of diagnostic tests 91 .…”

Section: Resultsmentioning

confidence: 99%

Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence

Silva

Galvão

Gomes

et al. 2013

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Revista da Sociedade Brasileira de Medicina Tropical 46(6):669-677, Nov-Dec, 2013http://dx.doi. org/10.1590/0037-8682-0104-2013 Address to: Dr a Juliana Saboia Fontenele e Silva. Lab. ABSTRACT We aimed to assess and synthesize the information available in the literature regarding the treatment of American tegumentary leishmaniasis in special populations. We searched MEDLINE (via PubMed), EMBASE, LILACS, SciELO, Scopus, Cochrane Library and mRCT databases to identify clinical trials and observational studies that assessed the pharmacological treatment of the following groups of patients: pregnant women, nursing mothers, children, the elderly, individuals with chronic diseases and individuals with suppressed immune systems. The quality of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. The available evidence suggests that the treatments of choice for each population or disease entity are as follows: nursing mothers and children (meglumine antimoniate or pentamidine), patients with renal disease (amphotericin B or miltefosine), patients with heart disease (amphotericin B, miltefosine or pentamidine), immunosuppressed patients (liposomal amphotericin), the elderly (meglumine antimoniate), pregnant women (amphotericin B) and patients with liver disease (no evidence available). The quality of evidence is low or very low for all groups. Accurate controlled studies are required to fi ll in the gaps in evidence for treatment in special populations. Post-marketing surveillance programs could also collect relevant information to guide treatment decision-making.

show abstract

“…Cutaneous disease is less common than visceral or mucosal disease in transplant recipients, with reports of two cases of classic disease, one case of disseminated disease caused by Leishmania major , one case of nodular disease, and two cases (one a recurrence) of post-Kala-Azar dermal leishmaniasis caused by Leishmania infantum [ 45 ]. A case of reactivation of a dormant cutaneous Leishmania infection in a renal transplant recipient from Bolivia who had undergone a renal transplant 2 months earlier and was living in a nonendemic area serves as a valuable teaching point about latent infection [ 46 ].…”

Section: Parasitic Skin and Soft Tissue Infectionsmentioning

confidence: 96%

Skin and soft tissue infections in the transplant population

Kotton

2008

Curr Infect Dis Rep

View full text Add to dashboard Cite

Solid organ and hematopoietic stem cell transplant recipients are more likely to develop skin and soft tissue infections, which may be caused by common or atypical pathogens. Skin and soft tissue anatomic abnormalities may act as portals of entry for infection, and may result from surgery, venous access, immunosuppressive medications, and other etiologies. Systemic infection may sometimes be recognized by investigation of skin manifestations. Many noninfectious processes of the skin and soft tissues can mimic infection, complicating the diagnosis. Prompt dermatologic consultation and skin biopsy are essential in this vulnerable population. Treatment of infection in transplant recipients may necessitate reduction of immunosuppression, in addition to other adjunctive therapies. Interesting and important new findings about skin and soft tissue infections in transplant recipients are the focus of this review.

show abstract

Reactivation of dormant cutaneous Leishmania infection in a kidney transplant patient

Cited by 35 publications

References 22 publications

Reactivation of Cutaneous Leishmaniasis after Renal Transplantation: A Case Report

Reactivation of Cutaneous Leishmaniasis after Renal Transplantation: A Case Report

Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence

Skin and soft tissue infections in the transplant population

Contact Info

Product

Resources

About